# Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)

Study · id `cardio:ct-nct03249285` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03249285](<https://clinicaltrials.gov/study/NCT03249285>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03249285

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT03249285. Randomized; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2018-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT03249285, source copy `cardio:ctgov-nct03249285-2017-08-15`, retrieved 2026-10-26)
- Start date: 2016-03 (registry gives no type) (ClinicalTrials.gov record NCT03249285, source copy `cardio:ctgov-nct03249285-2017-08-15`, retrieved 2026-10-26)
- Primary completion: 2018-03 (anticipated) (ClinicalTrials.gov record NCT03249285, source copy `cardio:ctgov-nct03249285-2017-08-15`, retrieved 2026-10-26)
- Completion: 2018-11 (anticipated) (ClinicalTrials.gov record NCT03249285, source copy `cardio:ctgov-nct03249285-2017-08-15`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT03249285, source copy `cardio:ctgov-nct03249285-2017-08-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03249285-2017-08-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)
- Acronym: PGX-HT
- Condition: Hypertension
- Intervention (Drug): Peri
- Intervention (Drug): HCTZ
- Lead sponsor: Ospedale San Raffaele
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Hydrochlorothiazide (`cardio:hydrochlorothiazide`)

## Provenance

Content hash: 62fe5385b6085a85973002b4296925090396e60538cb20fc752540485e13c776
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
